News | December 26, 2007

Canada Reactor Back in Business

December 27, 2007 - After a longer-than-expected maintenance shutdown, production of radioisotopes for molecular imaging and targeted therapy is back online at the National Research Universal (NRU) reactor in Chalk River, Ontario. The reactor was returned to service following direct intervention by the Canadian government, which in effect over-ruled the safety concerns of the Canadian Nuclear Safety Commission (CNSC).

The NRU entered a regularly scheduled maintenance shutdown on Nov. 18 (see A break in the supply chain on medicalphysicsweb). That shutdown resulted in an interruption in the supply of molybdenum-99 (Mo-99), a fission by-product that's used to make technetium-99m (Tc-99m) and iodine-131 (I-131). Tc-99m and I-131 are the predominant radionuclides used in diagnostic and therapeutic nuclear-medicine studies.

In early December, however, things started to get messy. Atomic Energy of Canada Limited (AECL), the government-owned company which runs the NRU reactor, announced an extension of the outage till early/mid-January to allow "modifications required for the installation of two new motor starters for the reactor cooling pump, and to connect the motors to an additional back-up power supply".

That announcement came against an already grim clinical backdrop, with thousands of seriously ill patients in North America facing delays to diagnostic procedures as a result of the disruption to isotope supply lines.

On Dec. 11, in response to concerns from the medical community, the Canadian parliament agreed a bill that temporarily suspended (for 120 days) the CNSC's oversight role, thus allowing the NRU to start up again even though it still did not fully meet safety standards.

The reactor was safely returned to service on Dec.16, which means that medical isotopes will by now be ready for removal, processing and distribution. In the coming weeks, AECL will complete the maintenance work during normal reactor operations.

The next time the NRU needs to be shut down for maintenance the AECL is likely to be better prepared. The agency has built two new reactors, MAPLE 1 and MAPLE 2, for exclusive production of medical isotopes. Originally scheduled to go online in 2004, they are now due to start up in October 2008 and October 2009, respectively.

• MDS Nordion (Ottawa, Canada), a leading supplier of medical isotopes, had reckoned it would take an $8-9 million earnings hit in its current quarter as a result of the NRU outage. With the reactor back online, however, the company anticipates less of a financial impact than previously estimated.

Source: Joe McEntee is editor of medicalphysicsweb. Additional reporting by physicsworld.com.

For more information: www.aecl.ca

Related Content

Example of full-dose, 10 percent low-dose and algorithm-enhanced low-dose. Image courtesy of Enhao Gong, Ph.D.

Example of full-dose, 10 percent low-dose and algorithm-enhanced low-dose. Image courtesy of Enhao Gong, Ph.D.

Feature | Contrast Media Injectors | April 11, 2019 | By Jeff Zagoudis
One of the most controversial issues in radiology in recent years has been the use of...
Non-Contrast MRI Effective in Monitoring MS Patients
News | Neuro Imaging | March 18, 2019
Brain magnetic resonance imaging (MRI) without contrast agent is just as effective as the contrast-enhanced approach...
Ultrasound Societies Urge FDA to Remove "Black Box" on Ultrasound Contrast Agents
News | Ultrasound Imaging | March 07, 2019
National and international ultrasound societies are urging the U.S. Food and Drug Administration to remove the “black...
Sponsored Content | Case Study | Contrast Media | January 30, 2019
The medical imaging market relies heavily on contrast media, injected into patients to increase the contrast of bodil
Sponsored Content | Videos | Contrast Media | January 22, 2019
ITN Contributing Editor Greg Freiherr speaks with Guerb
Videos | Artificial Intelligence | December 21, 2018
Enhao Gong, Ph.D., founder of Subtle Medical, an artificial intelligence (AI) company that develops products to help
Guerbet Showcases Diagnostic and Interventional Imaging Solutions at RSNA 2018
News | Interventional Radiology | December 12, 2018
Guerbet LLC USA highlighted new and next-level product offerings and partnerships in contrast media, injectors,...
Guerbet Launches Multi-Use OptiVantage Contrast Media Injector in Europe
Technology | Contrast Media Injectors | December 05, 2018
Contrast agent company Guerbet recently announced that the OptiVantage multi-use contrast media injector is now CE...
VigiLanz and Cincinnati Children's Commercialize Real-Time Acute Kidney Injury Tracking
News | Contrast Media | November 30, 2018
VigiLanz and Cincinnati Children’s Hospital Medical Center recently announced a collaboration that leverages Cincinnati...
Artificial Intelligence May Help Reduce Gadolinium Dose in MRI

Example of full-dose, 10 percent low-dose and algorithm-enhanced low-dose. Image courtesy of Enhao Gong, Ph.D.

News | Contrast Media | November 27, 2018
Researchers are using artificial intelligence (AI) to reduce the dose of a contrast agent that may be left behind in...